New Roche breast cancer drug delivers overall survival results

Roche's ($RHHBY) experimental breast cancer drug T-DM1 hit another study target, prompting analysts to predict regulatory approval during the first half of next year. After showing it can hold off tumor growth better than another treatment regimen, T-DM1 proved to extend the lives of patients with metastatic breast cancer as well. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.